Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Colorectal Cancer
Colorectal cancer treatment with nadroparin was safer than enoxaparin in terms of bleeding risk
October 5th, 2006
Nadroparin treatment was safer than enoxaparin for colorectal cancer patients in terms of postoperative bleeding risk. "The optimal thromboprophylactic dosage regimen of low-molecular-weight heparins in high-risk general surgery remains debatable. We performed a randomized, double-blind study to compare the efficacy and safety of nadroparin 2850 IU (0.3 mL) and enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism (VTE) after colorectal surgery for cancer," scientists in France reported. "Patients undergoing resection of colorectal adenocarcinoma were randomized to receive once daily either 2850 IU nadroparin or 4000 IU enoxaparin...
Source: Blood Weekly (2006-10-05)
|
